公开(公告)号：US12129263B2

公开(公告)日：2024-10-29

申请号：US17511193

申请日：2021-10-26

申请人： Denali Therapeutics Inc.

发明人： Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian Fox ,  Cinzia Maria Francini ,  Christopher R. H. Hale ,  Cheng Hu ,  Colin Philip Leslie ,  Maksim Osipov ,  Elena Serra ,  Zachary K. Sweeney ,  Arun Thottumkara

IPC分类号： C07D498/04 ,  A61K31/553 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P25/00 ,  A61P27/02 ,  A61P37/00 ,  A61P43/00 ,  C07D223/16 ,  C07D267/04 ,  C07D267/14 ,  C07D413/14 ,  C07D498/10 ,  C07D519/00

CPC分类号： C07D498/04 ,  C07D223/16 ,  C07D267/04 ,  C07D267/14 ,  C07D413/14 ,  C07D519/00

摘要： The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

公开(公告)号：US12128010B2

公开(公告)日：2024-10-29

申请号：US17833836

申请日：2022-06-06

申请人： NOVALIQ GMBH

发明人： Dieter Scherer ,  Ralf Grillenberger ,  Frank Löscher ,  Hartmut Voss

IPC分类号： A61K31/02 ,  A61F9/00 ,  A61K9/00 ,  A61K9/08 ,  A61P27/02

CPC分类号： A61K31/02 ,  A61F9/0008 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02

摘要： The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

公开(公告)号：US20240350593A1

公开(公告)日：2024-10-24

申请号：US18621336

申请日：2024-03-29

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ PARIS CITÉ ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

发明人： Francine BEHAR-COHEN ,  Raphael COHEN ,  Rinath LEVY-BOUKRIS ,  Min ZHAO

IPC分类号： A61K38/38 ,  A61K38/01 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

CPC分类号： A61K38/38 ,  A61K38/014 ,  A61K47/36 ,  A61P27/02 ,  A61K31/573

摘要： This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

公开(公告)号：US20240350402A1

公开(公告)日：2024-10-24

申请号：US18687993

申请日：2022-08-30

申请人： The Cleveland Clinic Foundation

发明人： Steven E. WILSON

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

CPC分类号： A61K9/0048 ,  A61K9/0051 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

摘要： The present invention relates to compositions, systems, and methods for treating a subject with a corneal injury and/or an existing corneal scar using a composition comprising an ACE-2 receptor antagonist (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the ACE-2 receptor antagonist is present in the composition at a concentration of about 0.2 mg/ml to 0.9 mg/ml or about 0.1 mg/ml to 2.0 mg/ml.

公开(公告)号：US12121585B2

公开(公告)日：2024-10-22

申请号：US18101636

申请日：2023-01-26

申请人： Ashvattha Therapeutics, Inc.

发明人： Jeffrey L. Cleland ,  Rishi Sharma ,  Santiago Appiani

IPC分类号： A61K47/59 ,  A61K31/404 ,  A61K49/00 ,  A61P27/02 ,  C08G73/02

CPC分类号： A61K47/595 ,  A61K31/404 ,  A61K49/0034 ,  A61K49/0054 ,  A61P27/02 ,  C08G73/028

摘要： Dendrimer compositions and methods for the treatment of one or more inflammatory and/or angiogenic diseases and/or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of the diseases of the eye, and/or for diagnosing the diseases and/or disorders of the eye. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be VEGFR tyrosine kinase inhibitors including sunitinib or analogues thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia/macrophages in retina/choroid.

公开(公告)号：US20240343814A1

公开(公告)日：2024-10-17

申请号：US18760575

申请日：2024-07-01

申请人： Viridian Therapeutics, Inc.

发明人： Vahe BEDIAN ,  Yang ZHAO

IPC分类号： C07K16/28 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/46

CPC分类号： C07K16/2863 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/461 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/94

摘要： Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US12109302B2

公开(公告)日：2024-10-08

申请号：US18227463

申请日：2023-07-28

申请人： Ocular Therapeutix, Inc.

发明人： Charles D. Blizzard ,  Rami El-Hayek ,  Michael Goldstein ,  Peter Jarrett ,  Andrew Vanslette

IPC分类号： A61K9/00 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

CPC分类号： A61K9/0051 ,  A61K38/13 ,  A61K47/10 ,  A61K47/22 ,  A61P27/02

摘要： Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US20240316219A1

公开(公告)日：2024-09-26

申请号：US18558919

申请日：2022-05-02

申请人： NORTH CAROLINA STATE UNIVERSITY ,  THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

发明人： Brian Gilger ,  Elizabeth Crabtree ,  Matthew L. Hirsch

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61P27/02 ,  C07K14/54 ,  C12N15/86

CPC分类号： A61K48/005 ,  A61K9/0048 ,  A61K48/0075 ,  A61P27/02 ,  C07K14/5428 ,  C12N15/86 ,  C12N2750/14143

摘要： The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic compositions comprising AAV-equine IL-10 for the treatment and/or prevention of various ocular diseases (e.g., non-infectious uveitis).

公开(公告)号：US20240316053A1

公开(公告)日：2024-09-26

申请号：US18574162

申请日：2022-06-23

申请人： LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD.

发明人： Yongzhi CHENG ,  Rui GU ,  Zenglin LIAN

IPC分类号： A61K31/519 ,  A61K31/198 ,  A61P27/02

CPC分类号： A61K31/519 ,  A61K31/198 ,  A61P27/02

摘要： A drug for treating dry eye, a method for improving wearing experience in populations with contact lens discomfort, and eye drops for treatment.